TOKYO -- Japan's Takeda Pharmaceutical is overhauling operations to stay competitive as a global drug developer, shedding long-held but noncore businesses and picking up prized assets from overseas.
The drugmaker is in late-stage talks to sell research reagent maker Wako Pure Chemical Industries to Fujifilm Holdings. The unit was formed in 1922 from Takeda's chemical operations, and retained the parent's name before becoming Wako in 1947. The duo remains closely linked even now, with members of Takeda's founding family holding Wako shares.
